Showing results (501-510 of 1,014) with videos related to
Sort By:
Pageof 102
Cancer Research Communications|March 20, 2025
Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function MutationShubhra Rastogi, Samantha Perino, Madhu Lal-Nag, et al.Cancer Research Communications|January 23, 2023
Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer SimulationChase Cockrell, David E AxelrodCancer Research Communications|January 23, 2023
Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitorsJoshy George, Yaohui Chen, Nourhan Abdelfattah, et al.Cancer Research Communications|January 5, 2026
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer TypesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.Cancer Research Communications|August 26, 2025
TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing SarcomaJessica D Daley, Elina Mukherjee, David Ferraro, et al.Cancer Research Communications|August 25, 2025
Seclidemstat (SP-2577) induces transcriptomic reprogramming and cytotoxicity in multiple fusion-positive sarcomasGalen C Rask, Cenny Taslim, Ariunaa Bayanjargal, et al.Cancer Research Communications|September 5, 2025
Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerBunpei Isoda, Masanobu Shiga, Shuya Kandori, et al.Cancer Research Communications|September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsJohn Powderly, Martina Imbimbo, Antoine Italiano, et al.Cancer Research Communications|May 19, 2022
8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADARKyle A Cottrell, Luisangely Soto Torres, Michael G Dizon, et al.Cancer Research Communications|October 24, 2022
STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancerSarah Athans, Nithya Krishnan, Swathi Ramakrishnan, et al.Pageof 102